Coeptis Therapeutics Hldgs Inc (COEP)

$15.16 +0.24 (1.61%)
Market Cap 79.67M
Revenue (ttm) 0.00
Net Income (ttm) -10.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 53,800
Avg Vol 71,560
Day's Range N/A - N/A
Shares Out 5.34M
Stochastic %K 52%
Beta -0.53
Analysts Strong Buy
Price Target $3.00

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-rela...

Industry: Biotechnology
Sector: Healthcare
Phone: 724 934 6467
Address:
105 Bradford Road, Suite 420, Wexford, United States
Iiii1ii
Iiii1ii Dec. 25 at 8:22 AM
$COEP Ultra Mega Short Skunk Imminent!
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 9:20 PM
$COEP
1 · Reply
Idontknow987
Idontknow987 Dec. 24 at 3:08 PM
$COEP bought 14.75 and 15.00
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:06 PM
$COEP
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:06 PM
$COEP
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:06 PM
$COEP
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:05 PM
$COEP
0 · Reply
ParabolicalSpartan
ParabolicalSpartan Dec. 24 at 3:04 PM
What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems -- $PSKY $VTGN $OCGN $COEP --
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:02 PM
$COEP undervalued. Winner.
0 · Reply
futuregssummeranalyst
futuregssummeranalyst Dec. 23 at 9:37 PM
$COEP not the direction we want. But very low volume. Waiting for that 10x volume day
0 · Reply
Latest News on COEP
Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Sep 23, 2025, 8:00 AM EDT - 3 months ago

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Jul 22, 2025, 8:36 AM EDT - 5 months ago

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

Jun 26, 2025, 8:34 AM EDT - 6 months ago

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

May 28, 2025, 8:28 AM EDT - 7 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

Apr 25, 2025, 8:33 AM EDT - 8 months ago

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Apr 17, 2025, 8:38 AM EDT - 9 months ago

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Mar 11, 2025, 8:34 AM EDT - 10 months ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 7, 2025, 8:37 AM EST - 10 months ago

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

Mar 6, 2025, 8:00 AM EST - 10 months ago

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

BURU

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

Feb 20, 2025, 9:00 AM EST - 11 months ago

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Feb 20, 2025, 7:27 AM EST - 11 months ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Feb 13, 2025, 8:39 AM EST - 11 months ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Feb 6, 2025, 8:08 AM EST - 11 months ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Jan 30, 2025, 8:27 AM EST - 11 months ago

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Jan 23, 2025, 8:09 AM EST - 1 year ago

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jan 22, 2025, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Jan 7, 2025, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Coeptis Therapeutics Announces Reverse Stock Split

Dec 27, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Announces Reverse Stock Split

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Dec 26, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Dec 12, 2024, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Dec 3, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Nov 7, 2024, 8:07 AM EST - 1 year ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Oct 24, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Oct 15, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Sep 19, 2024, 7:07 AM EDT - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Sep 5, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

Jun 20, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

May 30, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

May 8, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

May 2, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Apr 2, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Feb 26, 2024, 9:00 AM EST - 1 year ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Feb 7, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Jan 4, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Coeptis Therapeutics to Present at the Emerging Growth Conference

Dec 4, 2023, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Coeptis Therapeutics Announces $2 Million Private Placement

Oct 24, 2023, 8:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces $2 Million Private Placement

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Oct 9, 2023, 9:15 AM EDT - 2 years ago

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Oct 4, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Sep 14, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Sep 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Aug 30, 2023, 1:00 PM EDT - 2 years ago

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Aug 17, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Jun 16, 2023, 4:00 PM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Jun 14, 2023, 9:28 AM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

Jun 9, 2023, 7:00 AM EDT - 2 years ago

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

Iiii1ii
Iiii1ii Dec. 25 at 8:22 AM
$COEP Ultra Mega Short Skunk Imminent!
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 9:20 PM
$COEP
1 · Reply
Idontknow987
Idontknow987 Dec. 24 at 3:08 PM
$COEP bought 14.75 and 15.00
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:06 PM
$COEP
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:06 PM
$COEP
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:06 PM
$COEP
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:05 PM
$COEP
0 · Reply
ParabolicalSpartan
ParabolicalSpartan Dec. 24 at 3:04 PM
What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems -- $PSKY $VTGN $OCGN $COEP --
0 · Reply
NEWBIGTECH
NEWBIGTECH Dec. 24 at 3:02 PM
$COEP undervalued. Winner.
0 · Reply
futuregssummeranalyst
futuregssummeranalyst Dec. 23 at 9:37 PM
$COEP not the direction we want. But very low volume. Waiting for that 10x volume day
0 · Reply
PS600REVX
PS600REVX Dec. 23 at 7:52 PM
$COEP crazy low volume and a few impatient weak hands. I loaded a bit more
1 · Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Dec. 23 at 5:59 PM
$COEP Z-SQUARED MERGER https://investors.coeptistx.com/static-files/aa06e5b7-3e73-44e0-8c1b-795aecc09b7d
0 · Reply
Iiii1ii
Iiii1ii Dec. 23 at 3:23 PM
$COEP
0 · Reply
Iiii1ii
Iiii1ii Dec. 23 at 7:56 AM
$COEP
0 · Reply
futuregssummeranalyst
futuregssummeranalyst Dec. 22 at 9:06 PM
$COEP
0 · Reply
Stokroulette
Stokroulette Dec. 22 at 7:47 PM
$COEP imagine when this hits those million volume numbers
0 · Reply
AllAmerican82ndAirborne
AllAmerican82ndAirborne Dec. 22 at 7:34 PM
$COEP Let her cook
0 · Reply
Herrm
Herrm Dec. 22 at 7:16 PM
$COEP
0 · Reply
Brione
Brione Dec. 22 at 6:14 PM
$COEP Link to the S4 filed today for anyone who wants to read it: https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319658824&type=HTML&symbol=COEP&cdn=e8cadbf8e8ea3721eda89ea069bb50c5&companyName=Coeptis+Therapeutics+Holdings+Inc.&formType=S-4%2FA&formDescription=%5BAmend%5D+Registration+of+securities%2C+business+combinations&dateFiled=2025-12-22
0 · Reply
The1Albatross
The1Albatross Dec. 22 at 6:06 PM
$COEP Carry on
2 · Reply
futuregssummeranalyst
futuregssummeranalyst Dec. 22 at 5:24 PM
$COEP is this good?
0 · Reply
Brione
Brione Dec. 22 at 5:06 PM
$COEP Merger has been approved by the boards and now just needs to be approved by shareholders. S4 doesn't give a date for the vote yet but does show 2026, so hopefully January.
1 · Reply